|  |
Teva in deal to buy generic rival IVAX for $7.4 billion
Nieuws van: FirstWord
Teva announced that it has signed a definitive agreement to acquire IVAX for about $7.4 billion. Teva CEO Israel Makov said that the acquisition of IVAX will create "what we believe will be the largest company in the generic industry." The deal is expected to close in late 2005 or early 2006, pending regulatory approval.
26 Jul 2005
|
|
|
|
Printen
Doorsturen